Neuropathology and therapeutic management of Alzheimer's disease - An update

Drugs of the Future

Volumn 33, Issue 5, 2008, Pages 433-446

  Kumar, Anil ^a   Dogra, Samrita ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; ANTIOXIDANT; APOLIPOPROTEIN E; BESIPIRDINE; BETA SECRETASE; CHOLINESTERASE INHIBITOR; COLOSTRININ; DNA VACCINE; DONEPEZIL; GALANTAMINE; GAMMA SECRETASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LINOPIRDINE; MEMANTINE; MONOAMINE OXIDASE INHIBITOR; MONOCLONAL ANTIBODY; N2 [2 (3,5 DIFLUOROPHENYL) 2 HYDROXYACETYL] N1 (6,7 DIHYDRO 5 METHYL 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL)ALANINAMIDE; NEUROTRANSMITTER; NEUROTROPHIC FACTOR; NONSTEROID ANTIINFLAMMATORY AGENT; NOOTROPIC AGENT; NUTRACEUTICAL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PRESENILIN 1; PRESENILIN 2; RIVASTIGMINE; SEX HORMONE; TARENFLURBIL; TAU PROTEIN; UNINDEXED DRUG; XALIPRODEN;

ALZHEIMER DISEASE; ANDROPAUSE; ASTROCYTE; BRAIN METABOLISM; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CLINICAL TRIAL; COGNITIVE DEFECT; DIARRHEA; DISEASE COURSE; DRUG TARGETING; ENDOCRINE FUNCTION; EXCITOTOXICITY; FOOD AND DRUG ADMINISTRATION; GENE MUTATION; GENETIC PREDISPOSITION; HORMONAL THERAPY; HUMAN; IMMUNOTHERAPY; INFLAMMATION; LIPID PEROXIDATION; MACROPHAGE ACTIVATION; MENOPAUSE; MICROGLIA; MISSENSE MUTATION; NERVE CELL LESION; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NONHUMAN; OLIGOMERIZATION; OXIDATIVE STRESS; PASSIVE IMMUNIZATION; PATHOPHYSIOLOGY; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; REVIEW; RISK ASSESSMENT; SENILE PLAQUE; TREATMENT OUTCOME;

EID: 45849089594     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2008.033.05.1192677     Document Type: Review

References (147)

1. LaFerla, F.M., Green, K.N., Oddo, S. Intracellular amyloid-beta in Alzheimer's disease. Nat Rev Neurosci 2007, 8(7): 499-509.
2. Smith, M.A. Alzheimer disease. Int Rev Neurobiol 1998, 42: 1-54.
3. Robert, P.H., Verhey, F.R.J., Byrne, E.J. et al. Grouping for behavioral and psychological symptoms in dementia: Clinical and biological aspects. Consensus paper of the European Alzheimer Disease Consortium. Eur Psychiatry 2005, 20(7): 490-6.
4. Fuentealba, R.A., Farias, G., Scheu, J., Bronfman, M., Marzolo, M.P., Inestrosa, N.C. Signal transduction during amyloid-beta peptide neurotoxicity: Role in Alzheimer's disease. Brain Res Brain Res Rev 2004, 47(1-3): 275-89.
5. Alzheimer, A. Über eine eigenartige Erkrankung der Hirnrinde. Allgemeine Zeitschrift fur Psychiatrie und Psychisch-Gerichtliche Medzine 1907, 64: 146-8.
6. Glenner, G.G., Wong, C.W. Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984, 120(3): 885-90.
7. Masters, C.L. Amyloid plaque core protein in Alzheimer's disease and Down syndrome. Proc Natl Acad Sci USA 1985, 82(12): 4245-9.
8. Goedert, M., Wischik, C.M., Crowther, R.A., Walker, J.E., Klug, A. Cloning and sequencing of the cDNA encoding core protein of the paired helical filament of Alzheimer disease: Identification as the microtubule-associated protein tau. Proc Natl Acad Sci USA 1988, 85(11): 4051-5.
9. Grundke-Iqbal, I., Iqbal, K., Tung, Y.C., Quinlan, M., Wisniewski, H.M., Binder, L.I. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA 1986, 83(13): 4913-7.
10. Wyss-Coray, T. Inflammation in Alzheimer disease: Driving force, bystander or beneficial response? Nat Med 2006, 12(9): 1005-15.
11. Markesbery, W.R. Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med 1997, 23(1): 134-47.
12. Hebert, L.E., Scherr, P.A., Bienias, J.L., Bennett, D.A., Evans, D.A. Alzheimer disease in the US population: Prevalence estimates using 2000 census. Arch Neurol 2003, 60(8): 1119-22.
13. Ernst, R.L., Hay, J.W. The US economic and social costs of Alzheimer's disease revisited. Am J Public Health 1994, 84(8): 1261-4.
14. Clark, C.M., Karlawiah, J.H. Alzheimer disease: Current concepts and emerging diagnostics and therapeutic strategies. Ann Intern Med 2003, 138(5): 400-10.
15. Cummings, J.L. Alzheimer's disease. N Engl J Med 2004, 351(1): 56-67.
16. Hua, X., Lei, M., Zhang, Y., Ding, J., Han, Q., Hu, G., Xiao, M. Long term D-galactose injection combined with ovariectomy serves as a new rodent model for Alzheimer's disease. Life Sci 2007, 80(20): 1897-905.
17. Klafki, H.W., Staufenbiel, M., Kornhuber, J., Wiltfang, J. Therapeutic approaches to Alzheimer's disease. Brain 2006, 129(Pt. 11): 2840-55.
18. Hardy, J., Selkoe, D.J. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 2002, 297(5580): 353-6.
19. Lambert, M.P., Barlow, A.K., Chromy, B.A. et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 1998, 95(11): 6448-53.
20. Hartley, D.M., Walsh, D.M., Ye, C.P. et al. Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci 1999, 19(20): 8876-84.
21. Weidemann, A., König, G., Bunke, D., Fischer, P., Salbaum, J.M., Masters, C.L., Beyreuther, K. Identification, biogenesis, and localization of precursors of Alzheimer's disease A4 amyloid protein. Cell 1989, 57(1): 115-26.
22. Esch, F.S., Keim, P.S., Beattie, E.C. et al. Cleavage of amyloid beta peptide during constitutive processing of its precursor. Science 1990, 248(4959): 1122-4.
23. Sisodia, S., Koo, E., Beyreuther, K., Unterbeck, A., Price, D.L. Evidence that beta-amyloid protein in Alzheimer's disease is not derived by normal processing. Science 1990, 248(4954): 492-5.
24. Verdile, G., Fuller, S., Atwood, C.S., Laws, S.M., Gandy, S.E., Martins, R.N. The role of beta amyloid in Alzheimer's disease: Still a cause of everything or only one who got caught? Pharmacol Res 2004, 50(4): 397-409.
25. Reddy, P.H. Amyloid precursor protein-mediated free radicals and oxidative damage: Implications for the development and progression of Alzheimer's disease. J Neurochem 2006, 96(1): 1-13.
26. Rottkamp, C.A., Atwood, C.S., Joseph, J.A., Nunomura, A., Perry, G., Smith, M.A. The state versus amyloid-beta: The trial of the most wanted criminal in Alzheimer disease. Peptides 2002, 23(7): 1333-41.
27. Smith, M.A., Casadesus, G., Joseph, J.A., Perry, G. Amyloid-beta and tau serve antioxidant functions in the aging and Alzheimer brain. Free Radic Biol Med 2002, 33(9): 1194-9.
28. Roder, H.M., Hutton, M.L. Microtubule-associated protein tau as a therapeutic target in neurodegenerative disease. Expert Opin Ther Targets 2007, 11 (4): 435-42.
29. Heston, L.L., White, J. Pedigrees of 30 families with Alzheimer's disease: Associations with defective organization of microfilaments and microtubules. Behav Genet 1978, 8(4): 315-31.
30. Paula-Barbosa, M., Tavares, M.A., Cadete-Leite, A. A quantitative study of frontal cortex dendritic microtubules in patients with Alzheimer's disease. Brain Res 1987, 417(1): 139-42.
31. Yoshida, H., Ihara, Y. Tau in paired helical filaments is functionally distinct from fetal tau: Assembly incompetence of paired helical filament-tau. J Neurochem 1993, 61(3): 1183-6.
32. Spires, T.L., Orne, J.D., Santacruz, K., Pitstick, R., Carlson, G.A., Ashe, K.H., Hyman, B.T. Region specific dissociation of neuronal loss and neurofibrillary pathology in a mouse model of tauopathy. Am J Pathol 2006, 168(5): 1598-607.
33. Andorfer, C., Acker, C.M., Kress, Y., Hof, P.R., Duff, K., Davies, P. Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J Neurosci 2005, 25(22): 5446-54.
34. Moreira, P.I., Zhu, X., Liu, Q. et al. Compensatory responses induced by oxidative stress in Alzheimer disease. Biol Res 2006, 39(1): 7-13.
35. Cross, C.E., Halliwell, B., Borish, W.A. et al. Oxygen radicals and human disease. Ann Intern Med 1987, 107(4): 526-45.
36. Smith, M.A., Sayre, L.M., Monnier, V.M., Perry, G. Radical AGEing in Alzheimer's disease. Trends Neurosci 1995, 18(4): 172-6.
37. Mecocci, P., MacGarvey, U., Beal, M.F. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann Neurol 1994, 36(5): 747-51.
38. Nunomura, A., Perry, G., Pappolla, R., Wade, R., Hirai, K., Chiba, S., Smith, M.A. RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. J Neurosci 1999, 19(6): 1959-64.
39. Perry, G., Taddeo, M.A., Petersen, R.B. et al. Adventitiously bound redox active iron and copper are at the center of oxidative damage in Alzheimer's disease. Biometals 2003, 16(1): 77-81.
40. Butterfield, D.A., Drake, J., Pocernich, C., Castegna, A. Evidence of oxidative damage in Alzheimer's disease brain: Central role for amyloid beta-peptide. Trends Mol Med 2001, 7(12): 548-54.
41. Smith, M.A., Kutty, R.K., Richey, P.L. et al. Heme oxygenase-1 is associated with neurofibrillary pathology of Alzheimer's disease. Am J Pathol 1994, 145(1): 42-7.
42. Zhu, X., Webber, K.M., Casadesus, G. et al. Mitotic and gender parallels in Alzheimer's disease: Therapeutic opportunities. Curr Drug Targets 2004, 5(6): 559-63.
43. Bowser, R., Smith, M.A. Cell cycle proteins in Alzheimer's disease: Plenty of wheels but no cycle. J Alzheimers Dis 2002, 4(3): 249-54.
44. Hirai, K., Aliev, G., Nunomura, A. et al. Mitochondrial abnormalities in Alzheimer's disease. J Neurosci 2001, 21 (9): 3017-23.
45. Jordan-Sciutto, K.L., Malaiyandi, L.M., Bowser, R. Altered distribution of cell cycle transcriptional regulators during Alzheimer's disease. J Neuropathol Exp Neurol 2002, 61(4): 358-67.
46. Tsujioka, Y., Takahashi, M., Tsuboi, Y., Yamamoto, T., Yamada, T. Localization and expression of cdc2 and cdk4 in Alzheimer brain tissue. Dement Geriatr Cogn Disord 1999, 10(3): 192-8.
47. Khurana, V., Lu, Y., Steinhilb, M.L., Oldham, S., Shulman, J.M., Feany, M.B. TOR-mediated cell cycle activation causes neurodegeneration in Drosophila tauopathy model. Curr Biol 2006, 16(3): 230-41.
48. Kalaria, R.N., Gravina, S.A., Schmidley, J.W., Perry, G., Harik, S.I. The glucose transporter of the human brain and bloodbrain barrier. Ann Neurol 1988, 24(6): 757-64.
49. Zhu, X., Raina, A.K., Lee, H., Casadesus, G., Smith, M.A., Perry, G. Oxidative stress signaling in Alzheimer's disease. Brain Res 2004, 1000(1-2): 32-9.
50. Verdile, G., Gandy, S.E., Martins, R.N. The role of presenilin and interacting proteins in the biogenesis of Alzheimer's beta amyloid. Neurochem Res 2007, 32(4-5): 609-23.
51. Borchelt, D.R., Thinakaran, G., Eckman, C.B. et al. Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron 1996, 17(5): 1005-13.
52. Lemere, C.A., Lopera, F., Kosik, K.S. et al. The E280A presenilin 1 Alzheimer mutation produces increased Abeta42 deposition and severe cerebellar pathology. Nat Med 1996, 2(10): 1146-50.
53. Xia, W., Zhang, J., Kholodenko, D. et al. Enhanced production and oligomerization of the 42-residue amyloid beta-protein by Chinese hamster ovary cells stably expressing mutant presenilis. J Biol Chem 1997, 272(12): 7977-82.
54. Nilsberth, C., Westlind-Danielsson, A., Eckman, C.B. et al. The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nat Neurosci 2001, 4(9): 887-93.
55. Scheuner, D., Eckman, C., Jensen, M. et al. Secreted amyloid beta-proteins similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 1996, 2(8): 864-70.
56. Hoozemans, J.J.M., O'Banion, M.K. The role of COX-1 and COX-2 in Alzheimer's disease pathology and the therapeutic potentials of non-steroidal anti-inflammatory drugs. Curr Drug Targets CNS Neurol Disord 2005, 4(3): 307-15.
57. McGeer, P.L., McGeer, E.G. The inflammatory response system of brain: Implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Brain Res Rev 1995, 21(2): 195-218.
58. De Servi, B., La Porta, C.A., Bontempelli, M., Comolli, R. Decrease of TGF-beta1 plasma levels and increase in nitric oxide synthase activity in leukocytes as potential biomarkers for Alzheimer's disease. Exp Gerontol 2002, 37(6): 813-21.
59. Malaguarnera, L., Motta, M., Di Rosa, M., Anzaldi, M., Malaguamera, M. Interleukin-18 and transforming growth factor-beta1 plasma levels in Alzheimer's disease and vascular dementia. Neuropathology 2006, 26(4): 307-12.
60. Saez, T.E., Pehar, M., Vargas, M., Barbeito, L., Maccioni, R.B. Astrocytic nitric oxide triggers tau hyperphosphorylation in hippocampal neurons. In Vivo 2004, 18(3): 275-80.
61. Saez, E.T., Pehar, M., Vargas, M., Barbeito, L., Maccioni, R.B. Production of nerve growth factor by beta-amyloid-stimulated astrocytes induces p75NTR-dependent tau hyperphosphorylation in cultured hippocampal neurons. J Neurosci Res 2006, 84(5): 1098-106.
62. Quintanilla, R.A., Orellana, D.I., González-Billault, C., Maccioni, R.B. Interleukin-6 induces Alzheimer type phosphorylation of tau protein by deregulating the cdk5/p35 pathway. Exp Cell Res 2004, 295(1): 245-57.
63. Campbell, I.L., Stadler, A.K., Atwa, Y., Pagenstecher, A., Asensio, V.C. Transgenic models to study the actions of cytokines in the central nervous system. Neuroimmunomodulation 1998, 5(3-4): 126-35.
64. Heyser, C.J., Masliah, E., Samimi, A., Campbell, I.L., Gold, L.H. Progressive decline in avoidance learning paralleled by inflammatory neurodegeneration in transgenic mice expressing interleukin-6 in the brain. Proc Natl Acad Sci USA 1997, 94(4): 1500-5.
65. Rojo, L.E., Fernández, J.A., Maccioni, A.A., Jimenez, J.M., Maccioni, R.B. Neuroinflammation: Implications for the pathogenesis and molecular diagnosis of Alzheimer's disease. Arch Med Res 2007, 39(1): 1-16.
66. Pappolla, M.A., Bryant-Thomas, T.K., Herbert, D. et al. Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Neurology 2003, 61(2): 199-205.
67. Kuo, Y.-M, Emmerling, M.R., Bisgaier, C.L., Essenburg, A.D., Lampert, H.C., Drumm, D., Roher, A.E. Elevated low-density lipoprotein in Alzheimer's disease correlates with brain Abeta 1-42 levels. Biochem Biophys Res Commun 1998, 252(3): 711-5.
68. Rojo, L., Sjöberg, M.K., Hernández, P., Zambrano, C., Maccioni, R.B. Roles of cholesterol and lipids in the etiopathogenesis of Alzheimer's disease. J Biomed Biotechnol 2006, 2006(3): 73976.
69. Desire, L., Bourdain, J., Loiseau, N. et al. RAC1 inhibition targets amyloid precursor protein processing by gamma-secretase and decreases Abeta production in vitro and in vivo. J Biol Chem 2005, 280(45): 37516-25.
70. Papassotiropoulos, A., Wollmer, M.A., Tsolaki, M. et al. A cluster of cholesterol-related genes confer susceptibility for Alzheimer's disease. J Clin Psychiatry 2005, 66(7): 940-7.
71. Hüll, M., Berger, M., Heneka, M. Disease-modifying therapies in Alzheimer's disease. How far have we come? Drugs 2006, 66(16): 2075-93.
72. Castellani, R.J., Zhu, X., Lee, H.G., Moreira, P.I., Perry, G., Smith, M.A. Neuropathology and treatment of Alzheimer disease: Did we lose the forest for the trees? Expert Rev Neurother 2007, 7(5): 473-85.
73. Selkoe, D.J. Alzheimer's disease is a synaptic failure. Science 2002, 298(5594): 789-91.
74. Castegna, A., Aksenov, M., Aksenova, M. et al. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: Creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radic Biol Med 2002, 33(4): 562-71.
75. Kasa, P., Rakonczay, Z., Gulya, K. The cholinergic system in Alzheimer's disease. Prog Neurobiol 1997, 52(6): 511-35.
76. Sims, N.R., Bowen, D.M., Allen, S.J., Smith, C.C., Neary, D., Thomas, D.J., Davison, A.N. Presynaptic cholinergic dysfunction in patients with dementia. J Neurochem 1983, 40(2): 503-9.
77. DeKosky, S.T., Harbaugh, R.E., Schmitt, F.A. et al. Cortical biopsy in Alzheimer's disease: Diagnostic accuracy and neurochemical, neuropathological and cognitive correlations. Intraventricular Bethanecol Study Group. Ann Neurol 1992, 32(5): 625-32.
78. Casadesus, G., Puig, E.R., Webber, K.M. et al. Targeting gonadotropins: An alternative option for Alzheimer disease treatment. J Biomed Biotechnol 2006, 206(3): 39508.
79. Letenneur, L., Commenges, D., Dartigues, J.F., Barberger-Gateau, P. Incidence of dementia and Alzheimer's disease in elderly community residents of south-western France. Int J Epidemiol 1994, 23(6): 1256-61.
80. Rocca, W.A., Hofman, A., Brayne, C. et al. Frequency and distribution of Alzheimer's disease in Europe: A collaborative study of 1980-1990 prevalence findings. The EURODEM-Prevalence Research Group. Ann Neurol 1991, 30(3): 381-90.
81. Petanceska, S.S., Nagy, V., Frail, D., Gandy, S. Ovariectomy and 17beta-estradiol modulate the levels of Alzheimer's amyloid beta peptides in brain. Neurology 2000, 54(12): 2212-7.
82. Bi, R., Foy, M.R., Vouimba, R.M, Thompson, R.F., Baudry, M. Cyclic changes in estradiol regulate synaptic plasticity through the MAP kinase pathway. Proc Natl Acad Sci USA 2001, 98(23): 13391-5.
83. Zhu, X., Raina, A.K., Perry, G., Smith, M.A. Alzheimer's disease: The two-hit hypothesis. Lancet Neurol 2004, 3(4): 219-26.
84. Crouch, P.J., Harding, S.M.E., White, A.R., Camakaris, J., Bush, A.I., Masters, C.L. Mechanisms of Abeta mediated neurodegeneration in Alzheimer's disease. Int J Biochem Cell Biol 2008, 40(2): 181-98.
85. Kryger, G., Silman, I., Sussman, J.L. Three-dimensional structure of a complex of E2020 with acetylcholinesterase from Torpedo californica. J Physiol (Paris) 1998, 92(3-4): 191-4.
86. Greenblatt, H.M., Kryger, G., Lewis, T., Silman, I., Sussman, J.L. Structure of acetylcholinesterase complexed with (-)-galanthamine at 2.3 A resolution. FEBS Lett 1999, 463(3): 321-6.
87. Farlow, M. A clinical overview of cholinesterase inhibitors in Alzheimer's disease. Int Psychogeriatrics 2002, 14(Suppl. 1): 93-126.
88. Jacobsen, J.S., Reinhart, P., Pangalos, M.N. Current concepts in therapeutic strategies targeting cognitive decline and disease modification in Alzheimer's disease. NeuroRx 2005, 2(4): 612-26.
89. Bullock, R. New drugs for Alzheimer's disease and other dementias. Br J Psychiatry 2002, 180(2): 135-9.
90. Schenk, D., Barbour, R., Dunn, W. et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999, 400(6740): 173-7.
91. Janus, C., Pearson, J., McLaurin, J. et al. Abeta peptide immunization reduces behavioral impairment and plaques in a model of Alzheimer's disease. Nature 2000, 408(6815): 979-82.
92. Morgan, D., Diamond, D.M., Gottschall, P.E.J. et al. Abeta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000, 408(6815): 982-5.
93. Bard, F., Cannon, C., Barbour, R. et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer's disease. Nat Med 2000, 6(8): 916-9.
94. Solomon, B. Generation of anti-beta amyloid antibodies via phage display technology towards Alzheimer's disease vaccination. Vaccine 2005, 23(17-18): 2327-30.
95. DeMattos, R.B., Bales, K.R., Cummins, D.J., Dodart, J.C., Paul, S.M., Holtzman, D.M. Peripheral anti-Abeta antibody alters CNS and plasma Abeta clearance and decreases brain Abeta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2001, 98(15): 8850-5.
96. Orgogozo, J.M., Gilman, S., Dartingues, J.F. et al. Subacute meningioencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003, 61(1): 46-54.
97. Bayer, A.J., Bullock, R., Jones, R.W. et al. Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology 2005, 64(1): 94-101.
98. Gilman, S., Koller, M., Black, R.S. et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005, 64(9): 1553-62.
99. Christensen, D.D. Alzheimer's disease: Progress in the development of anti-amyloid disease-modifying therapies. CNS Spectr 2007, 12(2): 113-23.
100. Walker, L.C., Ibegbu, C.C., Todd, C.W., Robinson, H.L., Jucker, M., LeVine, H. 3rd, Gandy, S. Emerging prospects for the disease-modifying treatment of Alzheimer's disease. Biochem Pharmacol 2005, 69(7): 1001-8.
101. Siemers, E., Skinner, M., Dean, R.A. et al. Safety, tolerability and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers. Clin Neuropharmacol 2005, 28(3): 126-32.
102. Citron, M. Strategies for disease modification in Alzheimer's disease. Nat Rev Neurosci 2004, 5(9): 677-85.
103. Rosenberg, R.N. Translational research on the way to effective therapy for Alzheimer disease. Arch Gen Psychiatry 2005, 62(11): 1186-92.
104. Golde, T.E. Alzheimer disease therapy: Can the amyloid cascade be halted? J Clin Invest 2003, 111(1): 11-8.
105. Weggen, S., Eriksen, J.L., Sagi, S.A., Pietrzik, C.U., Golde, T.E., Koo, E.H. Abeta42-lowering nonsteroidal anti-inflammatory drugs preserve intramembrane cleavage of the amyloid precursor protein(APP) and ErbB-4 receptor and signaling through the APP intracellular domain. J Biol Chem 2003, 278(33): 30748-54.
106. Weggen, S., Eriksen, J.L., Das, P. et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 2001, 414(6860): 212-6.
107. Silvestrelli, G., Lanari, A., Parnetti, L., Tomassoni, D., Amenta, F. Treatment of Alzheimer's disease: From pharmacology to a better understanding of disease pathophysiology. Mech Ageing Dev 2006, 127(2): 148-57.
108. Whitfield, J.F. Can statins put the brakes on Alzheimer's disease? Expert Opin Investig Drugs 2006, 15(12): 1479-85.
109. Pedrini, S., Carter, T.L., Prendergast, G., Petanceska, S., Ehrlich, M.E., Gandy, S. Modulation of statin-activated shedding of Alzheimer APP ectodomain by ROCK. PLoS Med 2005, 2(1): e18.
110. Heneka, M.T., Sastre, M., Dumitrescu-Ozimek, L. et al. Acute treatment with PPARgamma agonists pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV7171 transgenic mice. Brain 2005, 128(Pt. 6): 1442-53.
111. Sastre, M., Klockgether, T., Heneka, M.T. Contribution of inflammatory processes to Alzheimer's disease: Molecular mechanisms. Int J Dev Neurosci 2006, 24(2-3): 167-76.
112. In't Veld, B.A., Ruitenberg, A., Hofman, A. et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 2001, 345(21): 1515-21.
113. Lehmann, J.M., Lenhard, J.M., Oliver, B.B., Ringold, G.M., Kliewer, S.A. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steriodal anti-inflammatory drugs. J Biol Chem 1997, 272(6): 3406-10.
114. Gervais, F., Chalifour, R., Garceau, D. et al. Glycosaminoglycan mimetics: A therapeutic approach to cerebral amyloid angiopathy. Amyloid 2001, 8(Suppl. 1): 28-35.
115. Garceau, D., Gurbindo, C., Laurin, J. Safety, tolerability and pharmacokinetic profile of Alzhemed, an anti-amyloid agent for Alzheimer's disease, in healthy subjects. 7th Int Geneva/Springfield Symp Adv Alzheimer Ther (April 3-6, Geneva) 2002.
116. Geerts, H. NC-531 (Neurochem). Curr Opin Investig Drugs 2004, 5(1): 95-100.
117. Gibson, G.L., Douraghi-Zadeh, D., Parsons, R.B., Austen, B.M. Properties of ovine colostrinin (O-CLN) on the in vitro aggregation and toxicity of beta-amyloid. Neurobiol Aging 2004, 25: 592.
118. Rattray, M. Technology evaluation: Colostrinin, ReGen. Curr Opin Mol Ther 2005, 7(1): 78-84.
119. Bilikiewicz, A., Gaus, W. Colostrinin (a naturally occurring, proline-rich, polypeptide mixture) in the treatment of Alzheimer's disease. J Alzheimers Dis 2004, 6(1): 17-26.
120. Leszek, J., Inglot, A.D., Janusz, M., Byczkiewicz, F., Kiejna, A., Georgiades, J., Lisowski, J. Colostrinin proline-rich polypeptide complex from ovine colostrums - A long-term study of its efficacy in Alzheimer's disease. Med Sci Monit 2002, 8(10): PI193-6.
121. Cherny, R.A., Atwood, C.S., Xilinas, M.E. et al. Treatment with copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 2001, 30(3): 665-76.
122. Curtain, C.C., Ali, F., Volitakis, I. et al. Alzheimer's disease amyloid-beta binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits. J Biol Chem 2001, 276(23): 20466-73.
123. Szekely, C.A., Thorne, J.E., Zandi, P.P., Ek, M., Messias, E., Breitner, J.C., Goodman, S.N. Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: A systematic review. Neuroepidemiology 2004, 23(4): 159-69.
124. Aisen, P.S., Schafer, K.A., Grundman, M. et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression. A randomized controlled trial. JAMA - J Am Med Assoc 2003, 289(21): 2819-26.
125. Reines, S.A., Block, G.A., Morris, J.C. et al. Rofecoxib: No effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology 2004, 62(1): 66-71.
126. Scharf, S., Mander, A., Ugoni, A., Vajda, F., Christophidis, N. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology 1999, 53(1): 197-201.
127. Firuzi, O., Praticò, D. Coxibs and Alzheimer's disease: Should they stay or should they go? Ann Neurol 2006, 59(2): 219-28.
128. Frank, B., Gupta, S. A review of antioxidants and Alzheimer's disease. Ann Clin Psychiatry 2005, 17(4): 269-86.
129. Prasad, K.N., Cole, W.C., Prasad, K.C. Risk factors for Alzheimer's disease: Role of multiple antioxidants, non-steroidal anti-inflammatory and cholinergic agents alone or in combination in prevention and treatment. J Am Coll Nutr 2002, 21(6): 506-22.
130. Blesch, A., Tuszynski, M.H. Gene therapy and cell transplantation for Alzheimer's disease and spinal cord injury. Yonsei Med J 2004, 45(Suppl.): 28-31.
131. Grundman, M., Capparelli, E., Kim, H.T. et al. A multicenter, randomized, placebo controlled, multiple-dose, safety and pharmacokinetic study of AIT-082 (Neotrofin) in mild Alzheimer's disease patients. Life Sci 2003, 73(5): 539-53.
132. Barron, A.M., Fuller, S.J., Verdile, G., Martins, R.N. Reproductive hormones modulate oxidative stress in Alzheimer's disease. Antioxid Redox Signal 2006, 8(11-12): 2047-59.
133. Bowen, R.L., Smith, M.A., Harris, P.L. et al. Elevated luteinizing hormone expression colocalizes with neurons vulnerable to Alzheimer's disease pathology. J Neurosci Res 2002, 70(3): 514-8.
134. Bowen, R.L., Verdile, G., Liu, T.B. et al. Luteinizing hormone, a reproductive regulator that modulates the processing of amyloid-beta precursor protein and amyloid-beta deposition. J Biol Chem 2004, 279(19): 20539-45.
135. Iqbal, I., Grundke-Iqbal, I. Pharmacological approaches of neurofibrillary degeneration. Curr Alzheimer Res 2005, 2(3): 335-41.
136. Lau, L.F., Seymour, P.A., Sanner, M.A., Schachter, J.B. Cdk5 as a drug target for the treatment of Alzheimer's disease. J Mol Neurosci 2002, 19(3): 267-73.
137. Bhat, R.V., Budd Haeberlein, S.L., Avila, J. Glycogen synthase kinase 3: A drug target for CNS therapies. J Neurochem 2004, 89(6): 1313-7.
138. Birks, J., Flicker, L. Selegiline for Alzheimer's disease. Cochrane Database Syst Rev 2003, 1: CD000442.
139. Youdim, M.B., Fridkin, M., Zheng, H. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases. Mech Ageing Dev 2005, 126(2): 317-26.
140. Youdim, M.B., Weinstock, M. Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R) aminoindan-5-yl)-ethyl methyl carbamate]. Cell Mol Neurobiol 2001, 21(6): 555-73.
141. Metzger, E., Wissmann, M., Yin, N. et al. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature 2005, 437(7057): 436-9.
142. Perry, E.K., Tomlinson, B.E., Blessed, G., Bergmann, K., Gibson, B.E., Perry, R.H. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J 1978, 2(6150): 1457-9.
143. Narang, P.K., Cutlet, N.R. Pharmacotherapy in Alzheimer's disease: Basis and rationale. Prog Neuropsychopharmacol Biol Psychiatry 1986, 10(3-5): 519-31.
144. Whitford, G.M. Alzheimer's disease and serotonin: A review. Neuropsychobiology 1986, 15(3-4): 133-42.
145. Palmer, A.M., Francis, P.T., Benton, J.S. et al. Presynaptic serotonergic dysfunction in patients with Alzheimer's disease. J Neurochem 1987, 48(1): 8-15.
146. Coyle, J.T., Price, D.L., DeLong, M.R. Alzheimer's disease: A disorder of cortical cholinergic innervation. Science 1983, 219(4589): 1184-90.
147. Mohr, E., Mendis, T., Rusk, I.N., Grimes, J.D. Neurotransmitter replacement therapy in Alzheimer's disease. J Psychiatry Neurosci 1994, 19(1): 17-23.